The resistomes of Mycobacteroides abscessus complex and their possible acquisition from horizontal gene transfer

Abstract

Background Mycobacteroides abscessus complex (MABC), an emerging pathogen, causes human infections resistant to multiple antibiotics. In this study, the genome data of 1,581 MABC strains were downloaded from NCBI database for phylogenetic relatedness inference, resistance profile identification and the estimation of evolutionary pressure on resistance genes in silico. Results From genes associated with resistance to 28 antibiotic classes, 395 putative proteins (ARPs) were identified, based on the information in two antibiotic resistance databases (CARD and ARG-ANNOT). The ARPs most frequently identified in MABC were those associated with resistance to multiple antibiotic classes, beta-lactams and aminoglycosides. After excluding ARPs that had undergone recombination, two ARPs were predicted to be under diversifying selection and 202 under purifying selection. This wide occurrence of purifying selection suggested that the diversity of commonly shared ARPs in MABC have been reduced to achieve stability. The unequal distribution of ARPs in members of the MABC could be due to horizontal gene transfer or ARPs pseudogenization events. Most (81.5%) of the ARPs were observed in the accessory genome and 72.2% ARPs were highly homologous to proteins associated with mobile genetic elements such as plasmids, prophages and viruses. On the other hand, with TBLASTN search, only 18 of the ARPs were identified as pseudogenes. Conclusion Altogether, our results suggested an important role of horizontal gene transfer in shaping the resistome of MABC.

Mycobacteroides chelonae-abscessus group infection in a Paraguayan rainbow boa (Epicrates crassus)

“…Human infections without risk factors with local or disseminated lesions have already been reported (8). MCABC is intrinsically resistant to many classes of antibiotics, such as beta-lactams, aminoglycosides, and rifamycin (2). Despite the rapid spread and difficulties in treating MCABC, it is necessary to invest in developing safer, more rapid, and more effective treatments and diagnoses.…”